优赫得®在中国获批用于在新辅助治疗后残存病灶的HER2阳性早期乳腺癌患者的辅助治疗

美通社
Oct 08

此次获批基于DESTINY-Breast05 III期试验结果:优赫得®较T-DM1可降低53%侵袭性疾病复发或死亡风险优赫得®在中国获批的第二项早期乳腺癌适应症,进一步巩固其覆盖HER2阳性乳腺癌不同阶段的治疗布局 上海2026年10月8日 /美通社/ -- 阿斯利康今日宣布,国家药品监督管理局(NMPA)于2026年9月29日批准,由阿斯利康和第一三共共同开发与商业化的优赫得®(英文商品名:...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10